Answers are grounded in this paper and cite their sources.
The epidermal growth factor receptor, or EGFR, is one of the most frequently altered oncogenes in human cancer and is a critical therapeutic target. EGFR alterations span a broad spectrum, including gene amplification, point mutations, truncations, in-frame insertions or deletions, and fusions, yet their mutational distribution is cancer type-specific. This distribution impacts the effectiveness of EGFR-targeted therapies across EGFR-mutant cancers. This review will cover what is currently known about the EGFR-driven cancer landscape in the following cell lineages: lung, brain, colon, breast and bladder. This article is part of the discussion meeting issue 'Epidermal growth factor receptor after 40 years'.
No takes yet. Share an insight, caveat, or question.
Rios et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: